Lee S. Schwartzberg, MD, of the West Cancer Center, reports on this past year’s progress of the ACCC initiative to speed adoption of immunotherapeutics in community practices.
Lee S. Schwartzberg, MD, of West Cancer Center, reports on the progress of the ACCC Immuno-Oncology Institute to speed adoption of immunotherapeutics in community practices.
As innovations in immunotherapies multiply, cancer programs and practices must overcome care coordination and communication challenges across the nation’s health-care system to integrate these advances into effective patient care. A new report from the Association of Community Cancer Centers...
Lee S. Schwartzberg, MD, of West Cancer Center, reports on this past year’s progress of the ACCC initiative to speed adoption of immunotherapeutics in community practices.
Lee S. Schwartzberg, MD, of The West Clinic, reports on progress of the now year-old ACCC initiative to speed adoption of immunotherapeutics in community practices.
Lee S. Schwartzberg, MD, of The West Clinic, describes a new initiative of the Association of Community Cancer Centers, designed to speed the adoption of immunotherapeutics in the community setting, where 60% of cancer patients are treated.
In a phase III study reported in The Lancet Oncology, Schwartzberg et al found that the addition of rolapitant to serotonin (5-HT3) receptor antagonist and dexamethasone treatment significantly improved complete response rates in prevention of chemotherapy-induced nausea and vomiting in patients...